Adaptive Biotechnologies Corp (HAM:1HM)
€ 18.54 -1.295 (-6.53%) Market Cap: 2.98 Bil Enterprise Value: 2.86 Bil PE Ratio: 0 PB Ratio: 15.63 GF Score: 47/100

Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference Transcript

Jan 13, 2026 / 12:30AM GMT
Release Date Price: €15.54 (+17.29%)
Sebastian Sandler
JPMorgan Chase & Co - Analyst

Great. Thanks, everyone, for just joining us. I'm pleased to be joined by the Adaptive team. My name is Sebastien Sandler from Life Science Tools and Diagnostics team at JPMorgan. As usual, we'll have 20 or so minutes of presentation followed by Q&A.

And with that, I'll pass it off to Chad. Thanks, Chad.

Chad Robins
Adaptive Biotechnologies Corp - Chairman of the Board, Chief Executive Officer, Co-Founder

Thank you, Sebastian, for the opportunity to present at JPMorgan once again. Happy New Year to all of you in the room, and welcome to those of you who are listening on the webcast. As a quick reminder, I will be making forward-looking statements during my presentation, and I and my team will be as well during the Q&A. For those of you who are new to Adaptive, let me give you a quick refresher of who we are. M

y brother, Harlan and I founded the company 16 years ago at the Fred Hutchinson Cancer Research Institute, and we've been public since 2019. Today, we're about 620 employees

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot